# Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

> **NCT04120311** · PHASE1 · UNKNOWN · sponsor: **Targeted Therapy Technologies, LLC** · enrollment: 2 (actual)

## Conditions studied

- Macular Edema
- Radiation Retinopathy
- Branch Retinal Vein Occlusion
- Epiretinal Membrane
- Central Serous Retinopathy With Pit of Optic Disc
- Commotio Retinae
- Vitritis

## Interventions

- **DRUG:** Episcleral Dexamethasone

## Key facts

- **NCT ID:** NCT04120311
- **Lead sponsor:** Targeted Therapy Technologies, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04120311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04120311, "Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04120311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*